In This Article:
In the current landscape of the United States market, investors are closely monitoring mixed stock performances as they await key announcements such as the Federal Reserve's interest rate decision and developments in trade negotiations with China. Amid this backdrop, high growth tech stocks continue to capture attention for their potential to thrive despite economic uncertainties, making them a focal point for those seeking opportunities in an evolving market environment.
Top 10 High Growth Tech Companies In The United States
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
Super Micro Computer | 20.40% | 34.10% | ★★★★★★ |
Arcutis Biotherapeutics | 26.42% | 58.25% | ★★★★★★ |
Ardelyx | 20.63% | 59.87% | ★★★★★★ |
Travere Therapeutics | 28.83% | 64.80% | ★★★★★★ |
TG Therapeutics | 25.99% | 38.42% | ★★★★★★ |
Alnylam Pharmaceuticals | 23.67% | 61.11% | ★★★★★★ |
AVITA Medical | 27.81% | 55.17% | ★★★★★★ |
Alkami Technology | 22.46% | 76.67% | ★★★★★★ |
Ascendis Pharma | 35.16% | 60.26% | ★★★★★★ |
Lumentum Holdings | 21.34% | 120.49% | ★★★★★★ |
Click here to see the full list of 231 stocks from our US High Growth Tech and AI Stocks screener.
Let's explore several standout options from the results in the screener.
Alvotech
Simply Wall St Growth Rating: ★★★★★★
Overview: Alvotech, with a market cap of $2.51 billion, operates through its subsidiaries to develop and manufacture biosimilar medicines for patients globally.
Operations: Biotechnology is the primary revenue segment for Alvotech, generating $491.98 million.
Alvotech's strategic focus on biosimilars is evident with recent FDA approvals, such as SELARSDI and SIMLANDI, enhancing its competitive edge in the high-stakes biotech sector. With a projected annual revenue growth of 30.9% and an anticipated shift to profitability within three years, Alvotech is positioning itself strongly against industry norms. The company's R&D commitment is underscored by significant investments aimed at expanding its biosimilar portfolio, aligning with industry trends towards more cost-effective therapeutic alternatives. This approach not only capitalizes on immediate regulatory milestones but also sets the stage for sustained long-term growth amidst evolving healthcare demands.
-
Click to explore a detailed breakdown of our findings in Alvotech's health report.
-
Explore historical data to track Alvotech's performance over time in our Past section.
Agilysys
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Agilysys, Inc. is a company that develops and markets software-enabled solutions and services for the hospitality industry across North America, Europe, the Asia-Pacific, and India with a market cap of approximately $2.11 billion.